Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis, a third indication for the drug candidate. The Company will collaborate with the Cleveland Clinic through a new consulting agreement. “Synaptogenix is excited to work with this internationally recognized team of…
ÇFARË TË HIQET KY ARTIKU:
- , a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis, a third indication for the drug candidate.
- The Company will collaborate with the Cleveland Clinic through a new consulting agreement.
- “Synaptogenix is excited to work with this internationally recognized team of….
